Live Breaking News & Updates on Bispecific

Stay updated with breaking news from Bispecific . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.

United-states , Johnson-teclistamab , Rachel-kobos , Oncology-research-development , Johnson , Oncology-research , Johnson-innovative-medicine , Teclistamab , Multiple-myeloma , Bispecific ,

Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.

Anthony-perissinotti , Ryan-haumschild , Matthew-pianko , Practice-pearls , Immune-effector-cell , Associated-encephalopathyscoring , Pharmacy-times , Multiple-myeloma , Bispecific , Bispecific-antibodies , Adverse-event-profile

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Bispecifict-cell-engager , Beyond-therapy , Fl , Third-line , Bispecific , Odronextamab , Epcoritamab , Mosunetuzumab

Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

Practical guidance for institutions navigating bispecific therapy integration without prior experience is provided.

Kirollos-hanna , Ryan-haumschild , Sarah-rockwell , Ryan-cain , Peer-exchange , Melody-chang , Bispecifics , Local-treatment-centers , Rems , Operational-pressures , Compliance , Hospitalization

Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.

Sarah-rockwell , Ryan-cain , Ryan-haumschild , Kirollos-hanna , Peer-exchange , Melody-chang , Bispecifics , Local-treatment-centers , Rems , Operational-pressures , Compliance , Hospitalization

Optimizing Bispecific Use Through EMR Utilization

Considerations for enhancing bispecific drug effectiveness through strategic EMR utilization in healthcare are explored.

Bispecifics , Local-treatment-centers , Rems , Operational-pressures , Compliance , Hospitalization , Hospitalization-protocol , Bispecific , Bispecific-antibodies , Florida-cancer-specialists , Teclistamab

Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy.

NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.

Florida , United-states , Ryan-cain , Ryan-haumschild , Kirollos-hanna , Sarah-rockwell , Peer-exchange , Melody-chang , Risk-evaluation , Mitigation-strategy , Florida-cancer-specialists , Bispecifics

Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

Providers delve into considerations for continuation of optimal care when patients receiving bispecific therapy transition between care settings.

Ryan-haumschild , Kirollos-hanna , Ryan-cain , Sarah-rockwell , Peer-exchange , Melody-chang , Bispecifics , Local-treatment-centers , Rems , Operational-pressures , Compliance , Hospitalization

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Matthew-lunning , Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , T-cell-engagers , Beyond-therapy , Bispecifict-cell-engagers , Bites , Third-line-and-beyond , Third-line-therapy , Fl

Tazemetostat as Third-line and Beyond Therapy for FL

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Peter-martin , Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Beyond-therapy , Third-line-and-beyond , Third-line-treatment , Tazemetostat , Fl , Fl-treatment , Follicular-lymphoma-treatment